Cara Therapeutics Inc. (CARA)
Cara Therapeutics Statistics
Share Statistics
Cara Therapeutics has 4.57M shares outstanding. The number of shares has increased by 0.36% in one year.
| Shares Outstanding | 4.57M |
| Shares Change (YoY) | 0.36% |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | 0.05% |
| Shares Floating | 3.82M |
| Failed to Deliver (FTD) Shares | 153 |
| FTD / Avg. Volume | 0.39% |
Short Selling Information
The latest short interest is 942.53K, so 20.62% of the outstanding shares have been sold short.
| Short Interest | 942.53K |
| Short % of Shares Out | 20.62% |
| Short % of Float | 2.01% |
| Short Ratio (days to cover) | 2.2 |
Valuation Ratios
The PE ratio is -3.94 and the forward PE ratio is -6.31. Cara Therapeutics's PEG ratio is 0.13.
| PE Ratio | -3.94 |
| Forward PE | -6.31 |
| PS Ratio | 39.13 |
| Forward PS | 0.8 |
| PB Ratio | -60.8 |
| P/FCF Ratio | -4.51 |
| PEG Ratio | 0.13 |
Enterprise Valuation
Cara Therapeutics Inc. has an Enterprise Value (EV) of 31.22M.
| EV / Earnings | -0.44 |
| EV / Sales | 4.37 |
| EV / EBITDA | -0.5 |
| EV / EBIT | -0.53 |
| EV / FCF | -0.5 |
Financial Position
The company has a current ratio of 11.03, with a Debt / Equity ratio of 0.
| Current Ratio | 11.03 |
| Quick Ratio | 10.81 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -6.89 |
Financial Efficiency
Return on equity (ROE) is 15.43% and return on capital (ROIC) is 1264.03%.
| Return on Equity (ROE) | 15.43% |
| Return on Assets (ROA) | -1.62% |
| Return on Capital (ROIC) | 1264.03% |
| Revenue Per Employee | $713,700 |
| Profits Per Employee | $-7,086,700 |
| Employee Count | 10 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -398K |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by -52.84% in the last 52 weeks. The beta is 0.5, so Cara Therapeutics's price volatility has been higher than the market average.
| Beta | 0.5 |
| 52-Week Price Change | -52.84% |
| 50-Day Moving Average | 5.06 |
| 200-Day Moving Average | 4.18 |
| Relative Strength Index (RSI) | 49.76 |
| Average Volume (20 Days) | 38.89K |
Income Statement
In the last 12 months, Cara Therapeutics had revenue of 7.14M and earned -70.87M in profits. Earnings per share was -1.55.
| Revenue | 7.14M |
| Gross Profit | 7.14M |
| Operating Income | -58.38M |
| Net Income | -70.87M |
| EBITDA | -62.6M |
| EBIT | -58.38M |
| Earnings Per Share (EPS) | -1.55 |
Balance Sheet
The company has 37.9M in cash and 0 in debt, giving a net cash position of 37.9M.
| Cash & Cash Equivalents | 37.9M |
| Total Debt | 0 |
| Net Cash | 37.9M |
| Retained Earnings | -755.61M |
| Total Assets | 43.83M |
| Working Capital | 39.85M |
Cash Flow
In the last 12 months, operating cash flow was -60.92M and capital expenditures -1.05M, giving a free cash flow of -61.96M.
| Operating Cash Flow | -60.92M |
| Capital Expenditures | -1.05M |
| Free Cash Flow | -61.96M |
| FCF Per Share | -1.36 |
Margins
Gross margin is 100%, with operating and profit margins of -818.03% and -992.95%.
| Gross Margin | 100% |
| Operating Margin | -818.03% |
| Pretax Margin | -998.53% |
| Profit Margin | -992.95% |
| EBITDA Margin | -877.12% |
| EBIT Margin | -818.03% |
| FCF Margin | -868.19% |
Dividends & Yields
CARA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -30.1% |
| FCF Yield | -263.07% |
Analyst Forecast
The average price target for CARA is $12, which is 133% higher than the current price. The consensus rating is "Hold".
| Price Target | $12 |
| Price Target Difference | 133% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Dec 31, 2024. It was a backward split with a ratio of 1:12.
| Last Split Date | Dec 31, 2024 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | -27.3 |
| Piotroski F-Score | 4 |